Longitudinal study of soluble adhesion molecules in multiple sclerosis: Correlation with gadolinium enhanced magnetic resonance imaging

Neurology

Volumn 48, Issue 6, 1997, Pages 1557-1565

  Giovannoni, G ^a   Lai, M ^b   Thorpe, J ^b   Kidd, D ^b   Chamoun, V ^a   Thompson, A J ^a   Miller, D H ^b   Feldmann, M ^c   Thompson, E J ^b  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b Multiple Sclerosis NMR Research Unit   (United Kingdom)

^c CHARING CROSS HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CELL ADHESION MOLECULE; CORTICOSTEROID; GADOLINIUM PENTETATE; INTERCELLULAR ADHESION MOLECULE 1; METHYLPREDNISOLONE; OKT 4; PREDNISOLONE; VASCULAR CELL ADHESION MOLECULE 1;

ADULT; ARTICLE; BLOOD LEVEL; CLINICAL FEATURE; CLINICAL TRIAL; CONTRAST ENHANCEMENT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE COURSE; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL;

EID: 0030859353     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/WNL.48.6.1557     Document Type: Article

References (48)

1. Hartung H-P, Archelos JJ, Zielasek J, et al. Circulating adhesion molecules and inflammatory mediators in demyelination: a review. Neurology- 1995;45(suppl 6):22-32.
2. Cannella B, Raine CS. The adhesion molecule and cytokine profile of multiple sclerosis lesions. Ann Neurol 1995;37:424-435.
3. Gearing JH, Newman W. Circulating adhesion molecules in disease. Immunol Today 1993;14:506-507.
4. Koch AE, Halloran MM, Haskell CJ, Shah MR, Polverini PJ. Angiogenesis mediated by soluble E-selectin and vascular cell adhesion molecule-1. Nature 1995;376:517-519.
5. Bevilacqua MP. Endothelial-leukocyte adhesion molecules. Ann Rev Immunol 1993;11:767-804.
6. Vachula M, Van Epps DE. In vitro models of lymphocyte transendothelial migration. Invasion Metastasis 1992;12:66-81.
7. Sharief MK, Noon MA, Ciardi M, Cirelli A, Thompson EJ. Increased levels of circulating ICAM-1 in serum and cerebrospinal fluid of patients with active multiple sclerosis: correlation with TNF-α and blood-brain barrier damage. J Neuroimmunol 1993;43:15-22.
8. Tsukada N, Miyagi K, Matsuda M, Yanagisawa N. Increased levels of circulating intercellular adhesion molecule-1 in multiple sclerosis and human T-lymphotropic virus type 1-associated myelopathy. Ann Neurol 1993;33:646-649.
9. Hartung H-P, Michels M, Reiners K, et al. Soluble ICAM-1 serum levels in multiple sclerosis and viral encephalitis. Neurology 1993;43:2331-2335.
10. Rieckmann P, Martin S, Weichselbraun I, et al. Senal analysis of circulating adhesion molecules and the TNF receptor in serum from patients with multiple sclerosis: cICAM-1 is an indicator of relapse. Neurology 1994;44:2367-2372.
11. Tsukada N, Matsuda M, Miyagi K, Yanagisawa N. Increased levels of intercellular adhesion molecule-1 (ICAM-1) and tumour necrosis factor receptor in the cerebrospinal fluid of patients with multiple sclerosis. Neurology 1993;43:2679-2682.
12. Dore-Duffy P, Newman W, Balabanov R, et al. Circulating, soluble adhesion proteins in cerebrospinal fluid and serum of patients with multiple sclerosis: correlation with clinical activity. Ann Neurol 1995;37:55-62.
13. Matsuda M, Tsukada N, Miyagi K, Nobuo Y. Increased levels of soluble vascular cell adhesion molecule-1 (VCAM-1) in the cerebrospinal fluid and sera of patients with multiple sclerosis and human T lymphotropic virus type-1 associated myelopathy. J Neuroimmunol 1995;59:35-40.
14. Hartung H-P, Reiners K, Archelos JJ, et al. Circulating adhesion molecules and tumour necrosis factor receptor in multiple sclerosis: correlation with magnetic resonance imaging. Ann Neurol 1995;38:186-193.
15. Giovannoni G, Thorpe JW, Kidd D, et al. Soluble E-selectin in multiple sclerosis: raised concentrations in patients with primary progressive disease. J Neurol Neurosurg Psychiatry 1996;60:20-26.
16. Thompson AJ, Kermode AG, Wicks D, et al. Major differences in the dynamics of primary and secondary progressive multiple sclerosis. Ann Neurol 1991;29:53-62.
17. Kidd D, Thorpe JW, Kendall BE, et al. MRI dynamics of brain and spinal cord in progressive multiple sclerosis. J Neurol Neurosurg Psychiatry 1996;60:15-19.
18. Poser CM, Paty DW, Scheinberg L, et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 1983;13:227-231.
19. Thorpe JW, Kidd D, Moseley IF, et al. Serial gadolinium enhanced MRI of the brain and spinal cord in relapsing remitting multiple sclerosis. Neurology 1996;46:373-378.
20. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983;33:1444-1452.
21. Miller DH, Barkhof F, Berry I, Kappos L, Scotti G, Thompson AJ. Magnetic resonance imaging in monitoring the treatment of multiple sclerosis: concerted Action Guidelines. J Neurol Neurosurg Psychiatry 1991;54:683-688.
22. Whitaker JN, McFarland HF, Rudge P, Reingold SC. Outcomes assessment in multiple sclerosis clinical trials: a critical analysis. Multiple Sclerosis 1995;1:37-47.
23. Miller DH, Albert PS, Barkhof F, et al. Guidelines for the use of magnetic resonance techniques in monitoring the treatment of multiple sclerosis. Ann Neurol 1996;39:6-16.
24. Grossman RI, Gonzalez-Scarano F, Atlas SW, et al. Multiple sclerosis: gadolinium enhancement in MR imaging. Radiology 1986;161:721-725.
25. Miller DH, Rudge P, Johnson G, et al. Serial gadolinium enhanced magnetic resonance imaging in multiple sclerosis. Brain 1988;111:927-939.
26. Filippi M, Horsfield MA, Tofts PS, Barkhof F, Thompson AJ. Miller DH. Quantitative assessment of MRI lesion load in monitoring the evolution of multiple sclerosis. Brain 1995;118: 1601-1612.
27. Revesz T, Kidd D, Thompson AJ, Barnard RO, McDonald WI. A comparison of the pathology of primary and secondary progressive multiple sclerosis. Brain 1994;117:759-765.
28. Smith ME, Stone LA, Albert PS, et al. Clinical worsening in multiple sclerosis is associated with increased frequency and area of gadopentetate dimeglumine-enhancing magnetic resonance imaging lesions. Ann Neurol 1993;33:480-489.
29. Thompson AJ, Miller D, Youl B, et al. Serial gadolinium-enhanced MRI in relapsing/remitting multiple sclerosis of varying disease duration. Neurology 1992;42:60-63.
30. Wiebe S, Lee DH, Karlik SJ, et al. Serial cranial and spinal cord magnetic resonance imaging in multiple sclerosis. Ann Neurol 1992;32:643-650.
31. Van Oosten BW, Lai M, Barkhoff M, et al. A phase II trial of anti-CD4 antibodies in the treatment of multiple sclerosis. Multiple Sclerosis 1997 (in press).
32. Beck J, Rondot P, Catinot L, Falcoff E, Kirchner H. Wietzerbin J. Increased production of interferon gamma and tumour necrosis factor precedes clinical manifestation in multiple sclerosis: do cytokines trigger off exacerbations? Acta Neurol Scand 1988;78:318-323.
33. Rieckmann P, Albrecht M, Kitze B, et al. Tumour necrosis factor-α messenger RNA expression in patients with relapsing-remitting multiple sclerosis is associated with disease activity. Ann Neurol 1995;37:82-88.
34. Chofflon M, Juillard C, Juillard P, Gauthier G, Grau GE. Tumour necrosis factor α production as a possible predictor of relapse in patients with multiple sclerosis. Eur Cytokine Netw 1992;3:523-531.
35. Thompson EJ, Giovannoni G. Measurement of inflammatory mediators in serum and CSF. In: Hartung H-P, ed. The role of inflammatory mediators in demyelinating disorders of the CNS and PNS. Austin, Texas: Landes, 1997 (in press).
36. Woodroofe MN, Cuzner ML. Cytokine mRNA expression in inflammatory multiple sclerosis lesions: detection by non-radioactive in situ hybridization. Cytokine 1993;5:583-588.
37. Brosnan CF, Cannella B, Battistini L, Raine CS. Cytokine localisation in multiple sclerosis lesions: correlation with adhesion molecule expression and reactive nitrogen species. Neurology 1995;45(suppl 6):16-21.
38. Beck J, Rondot P, Jullien P, Wietzerbin J, Lawrence DA. TGF-β-like activity produced during regression of exacerbations in multiple sclerosis. Acta Neurol Scand 1991;84:452-455.
39. McDonald WI, Miller DH, Barnes D. The pathological evolution of multiple sclerosis. Neuropathol Appl Neurobiol 1992; 18:319-334.
40. Rodriguez M, Scheithauer BW, Forbes G, Kelly PJ. Ohgodendrocyte injury is an early event in lesions of multiple sclerosis. Mayo Clin Proc 1993;68:627-636.
41. Katz D, Taubenberger JK, Cannella B, McFarlin DE, Raine CS, McFarland HF. Correlation between magnetic resonance imaging findings and lesion development in chronic, active multiple sclerosis. Ann Neurol 1993;34:661-669.
42. Mehta RC, Pike GB, Enzmann DR. Improved detection of enhancing and nonenhancing lesions of multiple sclerosis with magnetization transfer. AJNR Am J Neuroradiol 1995; 16:1771-1778.
43. Filippi M, Campi A, Martinelli V, et al. Comparison of triple dose versus standard dose gadolinium-DTPA for detection of MRI enhancing lesions in patients with primary progressive multiple sclerosis. J Neurol Neurosurg Psychiatry 1995;59: 540-544.
44. Losseff NA, Kingsley DPE, McDonald WI, et al. Clinical and magnetic resonance imaging predictors of disability in primary and secondary progressive multiple sclerosis. Multiple Sclerosis 1996;1:218-222.
45. Barkhof F, Thompson AJ, Hodgkinson S, et al. Double-blind, placebo-controlled, MR monitored exploratory trial of chimeric anti-CD4 antibodies in MS. J Neuroimmunol 1995;(suppl 1):
46. Van der Lubbe PA, Dijkmans BA, Markusse HM, Nassander U, Breedveld FC. A randomized, double-blind, placebo-controlled study of CD4 monoclonal antibody therapy in early-rheumatoid arthritis. Arthritis Rheum. 1995;38:1097-1106.
47. Bochner BS, Klunk DA, Sterbinsky SA, et al. IL-13 selectively induces vascular cell adhesion molecule-1 expression in human endothelial cells. J Immunol 1995;154:799-803.
48. Cartwright JE, Whitely GSJ, Johnstone AP. The expression and release of adhesion molecules by human endothelial cell lines and their consequent binding of lymphocytes. Exp Cell Res 1995;217:329-335.